Teladoc Health (NYSE:TDOC) Stock Sees Unusually High Call Option Buying

Teladoc Health, Inc. (NYSE:TDOC) was the target of some unusual options trading on Thursday. Traders acquired 15,699 call options on the company. This represents an increase of approximately 132% compared to the average volume of 6,766 call options.

Key Headlines Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q3 results exceeded expectations. Revenue was $605.1 million, down approximately 3% year over year but above the roughly $588 million consensus estimate. The company reported a net loss of $0.15 per share, narrower than expected and improved from the prior-year loss. Teladoc Health Reports Third Quarter 2026 Results
• Positive Sentiment: Profitability guidance improved. Teladoc raised its full-year 2026 GAAP earnings-per-share outlook and reported stronger adjusted EBITDA, supporting the view that cost controls and operating improvements are beginning to offset stagnant or declining revenue. Teladoc Stock Rallies After Double Beat
• Positive Sentiment: BetterHelp’s insurance transition offered an additional catalyst. Insurance-related BetterHelp revenue reached $32 million in Q3, and management is targeting an insurance-exit run rate of at least $200 million. Teladoc also plans to repurchase convertible notes, which could reduce debt and potentially improve per-share value. Teladoc Targets BetterHelp Insurance Exit Run Rate
• Positive Sentiment: Trading activity showed strong speculative interest. Call-option volume was more than double its average, while the stock moved above its 200-day moving average, potentially attracting momentum-oriented buyers.
• Neutral Sentiment: Near-term guidance was mixed. Teladoc forecast fourth-quarter revenue in a range of $569 million to $615 million, reflecting continued uncertainty about demand and growth.
• Negative Sentiment: Analysts remain cautious. Stifel raised its price target to $6.50 but maintained a “hold” rating, while Needham reaffirmed its hold rating. Those targets remain below the current trading level, highlighting concerns about continued revenue declines and ongoing losses. Stifel Nicolaus rating

Teladoc Health Price Performance

Shares of NYSE TDOC traded up $1.84 during mid-day trading on Thursday, reaching $8.72. 20,077,667 shares of the company’s stock were exchanged, compared to its average volume of 5,096,983. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.89. The firm has a 50-day moving average price of $6.15 and a two-hundred day moving average price of $6.46. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -8.81 and a beta of 2.14.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%. The company had revenue of $605.10 million during the quarter, compared to analyst estimates of $588.14 million. During the same quarter last year, the firm posted ($0.28) EPS. The firm’s revenue for the quarter was down 3.4% on a year-over-year basis. As a group, sell-side analysts forecast that Teladoc Health will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles III sold 17,805 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the transaction, the chief executive officer directly owned 465,535 shares of the company’s stock, valued at $2,839,763.50. This represents a 3.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teladoc Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its holdings in Teladoc Health by 1.3% during the 1st quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock valued at $44,066,000 after acquiring an additional 107,400 shares during the period. Monaco Asset Management SAM bought a new stake in shares of Teladoc Health during the second quarter valued at approximately $26,864,000. Pale Fire Capital SE raised its holdings in Teladoc Health by 74.8% in the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock worth $18,522,000 after purchasing an additional 1,454,288 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in shares of Teladoc Health by 128.0% during the 1st quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock valued at $14,287,000 after buying an additional 1,471,631 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC boosted its position in shares of Teladoc Health by 1,017.4% in the 3rd quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider’s stock worth $9,571,000 after purchasing an additional 1,502,488 shares in the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Citigroup lowered their price objective on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research note on Monday, August 3rd. Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a report on Thursday. Canaccord Genuity Group dropped their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Bank of America raised their target price on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $7.57.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.